However, because SETD8 codifies for a histone-lysine N-methyltransferase and it can also be expressed in RCC, it is feasible that promoting miR-382 expression through the inhibition of circ-SAR1A may be a potential treatment for RCC. Here, SAR1A is linked to renal cell carcinoma.